Search

Your search keyword '"Corvo' R"' showing total 3 results
Start Over Author "Corvo' R" Publisher country:ie
3 results on '"Corvo' R"'

1. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Author

Francolini, G, Borghesi, S, Fersino, S, Magli, A, Jereczek-Fossa, B, Cristinelli, L, Rizzo, M, Corvo, R, Pappagallo, G, Arcangeli, S, Magrini, S, D'Angelillo, R, Francolini G., Borghesi S., Fersino S., Magli A., Jereczek-Fossa B. A., Cristinelli L., Rizzo M., Corvo R., Pappagallo G. L., Arcangeli S., Magrini S. M., D'Angelillo R. M., Francolini, G, Borghesi, S, Fersino, S, Magli, A, Jereczek-Fossa, B, Cristinelli, L, Rizzo, M, Corvo, R, Pappagallo, G, Arcangeli, S, Magrini, S, D'Angelillo, R, Francolini G., Borghesi S., Fersino S., Magli A., Jereczek-Fossa B. A., Cristinelli L., Rizzo M., Corvo R., Pappagallo G. L., Arcangeli S., Magrini S. M., and D'Angelillo R. M.

Abstract

Aim: To compare trimodality therapy (TMT) versus radical cystectomy (RC) and develop GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) for treatment of muscle-invasive bladder cancer (MIBC). Material and Methods: Prospective and retrospective studies comparing TMT and RC for MIBC patients were included. Qualitative and quantitative evaluation of evidence was made. Results: Ten studies were included in the analysis. Pooled analysis showed salvage cystectomy and pathological complete response rates after TMT of 12 % and 72–77.5 %, respectively. Pooled rates of G3-G4 GU toxicity and serious toxicity rate were 18 vs 3% and 45 vs 29 % for patients undergoing TMT vs RC, respectively. The panel assessed a substantial equivalence in terms of OS and CSS at 5 years between TMT and RC. Conclusions: TMT could be suggested as an alternative treatment to RC in non-metastatic MIBC patients, deemed fit for surgery.

Published
2021

2. In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy

Author

Alongi, F, Arcangeli, S, Cuccia, F, D'Angelillo, R, Di Muzio, N, Filippi, A, Jereczek-Fossa, B, Livi, L, Pergolizzi, S, Scorsetti, M, Corvo, R, Magrini, S, Alongi F., Arcangeli S., Cuccia F., D'Angelillo R. M., Di Muzio N. G., Filippi A. R., Jereczek-Fossa B. A., Livi L., Pergolizzi S., Scorsetti M., Corvo R., Magrini S. M., Alongi, F, Arcangeli, S, Cuccia, F, D'Angelillo, R, Di Muzio, N, Filippi, A, Jereczek-Fossa, B, Livi, L, Pergolizzi, S, Scorsetti, M, Corvo, R, Magrini, S, Alongi F., Arcangeli S., Cuccia F., D'Angelillo R. M., Di Muzio N. G., Filippi A. R., Jereczek-Fossa B. A., Livi L., Pergolizzi S., Scorsetti M., Corvo R., and Magrini S. M.

Published
2021

3. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Author

De Felice, F, Belgioia, L, Alterio, D, Bonomo, P, Maddalo, M, Paiar, F, Denaro, N, Corvo, R, Merlotti, A, Bossi, P, Pappagallo, G, D'Angelillo, R, Magrini, S, Arcangeli, S, Pappagallo, GL, D'Angelillo, RM, Magrini, SM, De Felice, F, Belgioia, L, Alterio, D, Bonomo, P, Maddalo, M, Paiar, F, Denaro, N, Corvo, R, Merlotti, A, Bossi, P, Pappagallo, G, D'Angelillo, R, Magrini, S, Arcangeli, S, Pappagallo, GL, D'Angelillo, RM, and Magrini, SM

Abstract

Purpose: To evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy and identify differences in clinical outcomes and severe toxicity rate. Methods: PICOS/PRISMA methods were used to identify studies on PubMed, EMBASE and Cochrane Library, 2005–2019. Results: Six randomized clinical trials (554 patients) were identified. Weekly cisplatin was not associated with significant overall survival (HR 1.13, 95 % CI 0.84–1.51) and progression-free survival (HR 1.23, 95 %CI 0.91–1.65) improvement compared with three-weekly regimen. Severe acute toxicity (RR 0.95), treatment compliance to chemotherapy (RR 1.67) and radiotherapy (RR 0.61) were similar between regimens. Conclusion: Weekly cisplatin is not associated with better clinical outcomes compared to three-weekly cisplatin. Three-weekly cisplatin chemoradiotherapy should be considered the standard approach in the management of locally advanced head and neck cancer. Methodologically robust RCTs designs are needed to improve the quality of evidence. Differences on long-term toxicity and cost-effectiveness remain to be tested.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results